Details for Patent: 8,546,143

Summary for Patent: 8,546,143

Title:	Compositions and methods for inhibiting expression of a target gene
Abstract:	The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is substantially identical to at least a part of a target gene and which is no more than 49, preferably less than 25, nucleotides in length, and which comprises a complementary (antisense) RNA strand having a 1 to 4 nucleotide overhang at the 3′-end and a blunt 5′-end. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target gene, as well as for treating diseases caused by expression of the target gene, at low dosages (i.e., less than 5 milligrams, preferably less than 25 micrograms, per kg body weight per day). The invention also relates to methods for inhibiting the expression of a target gene, as well as methods for treating diseases caused by the expression of the gene.
Inventor(s):	Roland Kreutzer, Stefan Limmer, Sylvia Limmer, Philipp Hadwiger
Assignee:	Alnylam Pharmaceuticals Inc
Application Number:	US12/894,018
Patent Claim Types: see list of patent claims	Use;

error: insufficient information

Drugs Protected by US Patent 8,546,143

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 8,546,143

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	101 00 586	Jan 9, 2001
Germany	101 55 280	Oct 26, 2001
Germany	10 158 411	Nov 29, 2001

International Family Members for US Patent 8,546,143

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	222953
Austria	297463
Austria	328075